The problem we're solving
Small and mid-size IND sponsors are caught between two bad options: sprawling enterprise safety databases built for large MAHs, or ad-hoc spreadsheet and email processes that don't scale and can't pass an FDA inspection.
AE Connect is the intake layer that sits in between — purpose-built for teams running one to ten studies, with AI-assisted triage, a validated case workflow, and E2B(R3)-compliant output. Right-sized for where you are, ready for where you're going.
Why we built it
Our founders have collectively spent 15+ years building pharmacovigilance programs at Gilead Sciences, Prothena Biosciences, Kura Oncology, and Geron Corporation. Every engagement involved the same manual, error-prone AE intake process.
We built AE Connect to solve the problem we lived.
The team
QORO Intelligence is a small, focused team. We work closely with every customer.
Daman Singh
15+ years in pharmaceutical quality assurance and pharmacovigilance. Previously at Gilead Sciences, Prothena Biosciences, Kura Oncology, and Geron Corporation. ASQ Certified Quality Auditor. Veeva Vault Certified Admin.
Raman Gill
Leads business development, partner relationships, and operational infrastructure at QORO Intelligence. Focused on bringing AE Connect to small and mid-size biotech programs across North America.
Delaware corporation. California team.
QORO Intelligence Inc. is incorporated in Delaware and operates out of the San Francisco Bay Area. Our engineering, product, and customer teams are all based in California.
We build in the open with our customers — beta participants work directly with our founders, not a support queue.
What's next
AE Connect is in active beta through June 30, 2026. We're working with a small cohort of IND sponsors to validate the platform against real production workflows before full commercial launch in Q3 2026.
If you're running an IND-stage program and want to shape what we build, the beta program is open. Apply here.